Approval for children aged two to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical study programCSU is a chronic skin ...

FDA expands Dupixent approval for children aged 2 to 11 years with chronic spontaneous urticaria symptomatic despite H1 antihistamine use.

Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,000 adults and adolescents aged 12 years and older ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is based on results from the pivotal ADEPT phase 2/3 ...

French drugmaker Sanofi SA SNY and its partner Regeneron Pharmaceuticals Inc. REGN on Wednesday secured U.S. Food and Drug ...

Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment If approved, Dupixent would be the first ...

Patients receiving dupilumab showed clinical improvement in nasal congestion and smell, and were less likely to require systemic corticosteroids or additional sino-nasal surgery. The Food and Drug ...

While it might seem a little intimidating at first, the process is designed to be simple. However, it’s good to know what to do if an injection doesn’t go exactly as planned. This article will walk ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) and Sanofi secured European Commission approval for Dupixent in moderate to severe ...

BP is a chronic, debilitating and relapsing skin disease with underlying type 2 inflammation characterized by intense itch and blisters, reddening of the skin and painful lesions TARRYTOWN, N.Y. and ...

Proportion of patients with complete response (UAS7=0).

Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous ...